Biomarker Consortium Project
Biomarker tools for early diagnosis and disease progression in Alzheimer’s disease (AD) remain key issues in AD drug development. Identification and validation of cost-effective, non-invasive methods to identify early AD and to monitor treatment effects in mild-moderate AD patients could revolutionize current clinical trial practice. Treatment prior to the onset of dementia may also ensure intervention occurs before irreversible neuropathology.
For more information on outlining Proteomic Analysis of ADNI Data, download the study strategies below.
